Supplemental Online Content

Fu F, Yu L, Zeng B, et al. Association of adjuvant hormone therapy timing with overall survival among patients with hormone receptor–positive human epidermal growth factor receptor–2–negative early breast cancer without chemotherapy. *JAMA Netw Open.* 2022;5(2):e2145934. doi:10.1001/jamanetworkopen.2021.45934

eTable 1. Missing Variables Data

eTable 2. Sensitivity Analyses Regarding the Association of TTH >150 Versus TTH <150 with OS

eFigure. Flow Diagram of Exclusions for National Cancer Database (NCDB)

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. Missing Variables Data.

Variable	NCDB Missing (n)*	
Age	0	
Sex	0	
Race	0	
Insurance type	0	
Setting	3757	
Facility type	0	
Charlson Comorbidity Index (CCI)	0	
Histology	0	
Grade	0	
Pathological stage	0	
Hormone receptor	0	
Surgery	29	
Radiotherapy	310	
*Not exclusive: some natients may have had more than one variable		

^{*}Not exclusive: some patients may have had more than one variable missing.

eTable 2. Sensitivity Analyses Regarding the Association of TTH>150 Versus TTH≤150 with OS

Model	Hazard Ratio (95% CI)	P Value
Unweighted	1.32 (1.19-1.47)	<.001
Propensity score based		
Weighted (IPTW)	1.31 (1.26-1.35)	<.001
IPTW with stabilized weight	1.31 (1.19-1.45)	<.001
IPTW with a generalized	1.23 (1.18-1.27)	<.001
boosted regression model		
Propensity Score Matching	1.41 (1.13-1.76)	.002
(PSM) ^a		
PS regression adjustment	1.29 (1.16-1.43)	<.001

Abbreviations: IPTW, inverse probability of treatment weighting; OS, overall survival; PS, propensity score.

^a Propensity score matching (PSM) was conducted using the nearest neighbour-matching with different calipers values (0.5, 0.1, 0.01, 0.001) for 1:1 matching and 0.5 for 1:2 matching. All results are stable. The result of a 1:1 match with a caliper of 0.001 was shown here.

eFigure 1. Flow Diagram of Exclusions for National Cancer Database (NCDB)

Patients with breast cancer according to the NCDB, 2004-2014 (N=2,246,280)

Excluded:

Non-carcinoma (sarcoma or phyllodes tumor) (N =3,015)

Non-invasive breast cancer (N =458,765)

Prior malignancy (N =416,842)

Stage IV, metastatic disease and unknown pathological stage (N =261,263)

ER-negative and PR-negative, or ER and PR data missing (N=219,665)

No surgery and surgery status unknown (N =3,015)

Received hormone therapy and hormone therapy status missing (N =189,575)

Received neoadjuvant systematic therapy (N =146,922)

Unknown time to definitive surgery or to hormone therapy, or hormone therapy before surgery (N = 42,980)

Received chemotherapy (N=187,928)

Follow-up time less than 8 months or unknown follow-up time (N = 54,525)

Received immunotherapy or immunotherapy status unknown (N =1,647)

HER2-positive or HER2 status unknown (N =111,924)

Cases with missing data (N =4,084)

